Bristol-Myers Squibb and Samsung BioLogics have expanded their existing manufacturing agreement in which Samsung will manufacture commercial drug substances and drug product for several BMS biologics at its Incheon manufacturing site in Korea. Financial terms were not disclosed. The companies entered their first manufacturing agreement in July 2013 for the production of a single commercial antibody cancer drug substance.   Samsung’s Incheon production facilities provide process development, drug...